STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.
Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze JF, Hindie E, Battistella M, Dumaz N, Mourah S, Lebbe C; GCC (French Group of Skin Cancer).
Delyon J, et al. Among authors: avril mf.
J Invest Dermatol. 2018 Jan;138(1):58-67. doi: 10.1016/j.jid.2017.07.839. Epub 2017 Aug 24.
J Invest Dermatol. 2018.
PMID: 28843487
Free article.
Clinical Trial.